Cancer is frequently considered to be a disease of the cell cycle. As such, it is not surprising that the deregulation of the cell cycle is one of the most frequent alterations during tumor development. Cell cycle progression is a highlyordered and tightly-regulated process that involves multiple checkpoints that assess extracellular growth signals, cell size, and DNA integrity. Cyclin-dependent kinases (CDKs) and their cyclin partners are positive regulators or accelerators that induce cell cycle progression; whereas, cyclindependent kinase inhibitors (CKIs) that act as brakes to stop cell cycle progression in response to regulatory signals are important negative regulators. Cancer originates from the abnormal expression or activation of positive regulators and functional suppression of negative regulators. Therefore, understanding the molecular mechanisms of the deregulation of cell cycle progression in cancer can provide important insights into how normal cells become tumorigenic, as well as how new cancer treatment strategies can be designed.
Introduction
Cancer cells differ from normal cells in many important characteristics. These include the loss of differentiation, selfsufficiency in growth signals, limitless replicative potential, increased invasiveness, and decreased drug sensitivity (Hanahan and Weinberg, 2000) . These differences do not arise simply from uncontrolled cellular growth, but rather from a cellular evolution. The increased incidence of cancer as a function of age has long been interpreted to suggest that the progressive acquisition of mutations and epigenetic abnormalities in the expression of multiple genes that have highly diverse functions are required for tumorigenesis. An important group of these genes is involved in cell cycle checkpoints, which are positions of control that ensure the order of events in the cell cycle, and that integrate DNA repair with cell cycle progression.
Cell cycle transition is an ordered, tightly-regulated process that involves multiple checkpoints that assess extracellular growth signals, cell size, and DNA integrity. The somatic cell cycle is divided into four distinct phases (Fig. 1 ). During two of these phases, the cells execute the basic events in cell division like generation of a single and faithful copy of its genetic material (synthetic or S phase) and partitioning of all the cellular components between the two identical daughter cells (mitosis or M phase). The two other phases of cell cycle represent gap periods (G1 and G2), during which the cells prepare themselves for the successful completion of the S and M phases, respectively. When the cells cease proliferation, due either to specific antimitogenic signals or to the absence of proper mitogenic signaling, then they exit the cycle and enter a non-dividing, quiescent state, known as G0. In addition, the cell cycle may be arrested at the G1 or G2 checkpoints that assess cell size, extracellular growth signals, and DNA integrity.
The molecular analysis of human tumors has shown that cell cycle regulators are frequently mutated in human tumors, which underscores how important the maintenance of cell cycle commitment is in the prevention of human cancer. This review will focus on the abnormalities of the cell cycle control protein and their potential impact on cancer treatment. But, to understand the abnormalities of the cell cycle regulatory protein in cancer, we first need to consider their role in the normal cell cycle.
Control of Cell Cycle Progression
The molecular machinery of the cell cycle (the factors that control the various stages in the progression from G1 to M) has been substantially examined during the past decade *To whom correspondence should be addressed. Tel: Fax: 82-2-977-0381 E-mail: sjlee@kcch.re.kr (Pardee et al., 1989; Xiong et al., 1991; Sherr et al., 1993; Morgan et al., 1995; Hwang et al., 1998; Zhan et al., 1999; Raleigh et al., 2000) The heart of the regulatory apparatus during the cell cycle progression is a family of enzymes, called the cyclindependent kinases (CDKs). The active forms of CDKs are a complex of at least two proteins, a kinase and a cyclin (Table  1) . They often contain other proteins with poorly understood functions. These complexes undergo changes in the kinase and cyclin components that are believed to drive the cell from one stage of the cell cycle to another (Pardee et al., 1989; Xiong et al., 1991; Sherr et al., 1993; Morgan et al., 1995; Hwang et al., 1998; Zhan et al., 1999; Raleigh et al., 2000) . According to this paradigm, the cell cycle is determined by the constellation of proteins that are activated or inactivated by phosphorylation, a result of the activity of the CDKs during that stage (Fig. 1) . In mammalian cells, a succession of kinase subunits (CDK4, CDK6, CDK2, and CDC2) is expressed along with a succession of cyclins (cyclin D, E, A, and B), as the cells progress from G1 to mitosis. CDK4 and CDK6 complexed with one of several D-type cyclins functions early in the G1 phase, probably in response to growth factors. CDK2 that complexed with cyclin E, cyclin A, or both is essential for the G1 S transition and DNA replication, respectively. CDC2 that complexed with cyclin A and cyclin B is essential for mitosis. Additional CDKs and cyclins will be added to this list ( Table 1) .
The passage of cells from one stage of the cell cycle to another is tightly regulated by a wealth of controls that act on the transcription of cyclin genes, the degradation of cyclins, and modification of the kinase subunits by phosphorylation. A number of positive or negative feedback loops also contribute to the cell cycle progression (Fig. 2) . CDK activity is positively regulated by the association with the cyclins, and by phosphorylation of the T-loop threonine by the CDKactivating kinase (CAK), a serine/threonine kinase that is also involved in transcription and DNA repair (Nigg, 1996) . Inhibitory phosphorylation of adjacent threonine and tyrosine residues (T14/Y15 in CDC2) is mediated by dual specific kinases (Wee1 and MYT1). This inhibition is relieved when the CDC25 phosphatases dephosphorylate these residues, which triggers entry into mitosis (Morgan, 1997; Ekholm and Reed, 2000) . CDKs and their cyclin partners are positive regulators or accelerators that induce cell cycle progression; whereas, important negative regulators, such as cyclindependent kinase inhibitors (CKIs), act as brakes to stop the cell cycle progression in response to regulatory signals (Fig.  2) . By direct association with CDK, CKIs can negatively regulate CDK activity. There are two types of CKIs. The four members of the INK family, INK4A (p16), INK4B (p15), INK4C (p18), and INK4D (p19), exert their inhibitory activity by binding to CDK4 and CDK6, and preventing their association with D-type cyclins. The three members of the CIP/KIP family, CIP1 (p21), KIP1 (p27), and KIP2 (p57), form heterotrimeric complexes with the G1/S CDKs. CKIs are induced in response to different cellular processes (Sherr and Roberts, 1999; Sherr, 2000) . For instance, in quiescent cells, the KIP1 levels are generally high. CIP1 is one of the effectors of p53, a tumor suppressor that is important in the DNA damage checkpoint.
The critical point of cell cycle control is the restriction Fig. 1 . Progression of cell cycle. Somatic cell cycle consists of four distinct phases: initial growth (G1), DNA synthesis (S), a gap (G2), and mitosis (M). The critical point of cell cycle control is the restriction point. After passing this point, the cell cycle is irreversibly committed to the next cell division. Cyclin H Cdk8
Cyclin C Cdk9
Cyclin T point. After passing this point, the cell is irreversibly committed to the next phase of the cell cycle (Fig. 1) . The restriction point control is mediated by the cyclin D and cyclin E-dependent kinases. The primary substrates of CDK4/6 and CDK2 in G1 progression are the members of the retinoblastoma protein family pRB, p107, and p130 ( Fig. 2 ) (Morgan, 1997; Adams, 2001 ). These molecules function as negative regulators at the restriction point. One important target of pRB for regulating the early G1 cell cycle progression is the E2F family of transcription factors (Harbour and Dean, 2000) . E2Fs regulate the expression of a host of genes that mediates both restriction point transversals, such as cyclin E, and the S phase progression, such as dihydrofolate reductase and thymidylate synthase (Fig. 2) . Moreover, pRb has some CDK-independent functions, such as the repression of some promoters and RNA pol III activity (Adnane et al., 1995; Sellers et al., 1995; Weintraub et al., 1995; White et al., 1996) . Therefore, the re-introduction and expression of pRb into tumor cells may arrest growth by mechanisms that are independent of the CDK complex formation.
Abnormalities in the Cell Cycle Control Proteins in Cancer
Abnormalities in Cyclins and CDKs: In recent years, it has become apparent that tumorigenesis is frequently associated with mutations or abnormalities in the expression of various cyclins, CDKs and CKIs in several types of human cancers Sgambato et al., 1998) . In 1991, a presumptive oncogene that is composed of the parathyroid hormone gene (PRAD1) that fused to the gene that encodes cyclin D1 was identified in a human parathyroid adenoma (Heichman and Roberts, 1994; King et al., 1994) . This observation provided the first clue that cyclins might be directly involved in some human cancers. Subsequently, evidence was presented for the involvement of cyclins in other human cancer cells. These included B cell lymphoma and breast, gastric, colon and esophageal carcinomas, as well as several other types of cancers (Hunter and Pines, 1994) . Indeed, the increased expression of cyclin D1 is one of the most frequent abnormalities in human cancer, since it occurs in ~60% of breast cancers, 40% of colorectal cancers, 40% of squamous carcinoma of the head and neck, and 20% of prostate cancers Han et al., 1998; Sgambato et al., 1998) . Consistant with these results, cyclin D1 substitutes or partially substitutes for certain oncogenes in the cellular transformation assay (Hinds et al., 1994; Lovec et al., 1994) . The cyclin E gene, which acts in late G1, is also overexpressed and dysregulated in a variety of human cancers (Malumbres and Barbacid, 2001) . The amplification and overexpression of CDKs and its regulators have rarely been described in human cancers. Some reports demonstrated that the CDK4 gene is overexpressed in certain tumor cell lines (Hunter and Pines, 1994) . As with cyclins, however, a general involvement of CDKs in cancer has yet to be demonstrated.
Abnormalities in CKIs
Two families of CKIs have been characterized, based on their specificity. The first is the INK4 family, which includes p15 (INK4B), p16 (INK4A), p18 (INK4C), and p19 (INK4D) (Sherr and Roberts, 1995) . The INK4 family of proteins specifically targets the cyclin D-dependent kinases (CDK4 and CDK6) (Sherr and Roberts, 1995; Ruas and Peters, 1998) . The INK4A (p16) protein, which was originally identified as a CDK4-interacting protein that inhibits CDK4 kinase activity (Serrano et al., 1993) , has been mapped to chromosome 9p21 . Due to a hot spot of genomic alterations in cancers, intense studies have focused on the role of INK4A in tumorigenesis. Mutations and deletions of INK4A genes are frequently found in a variety of human malignancies and transformed cells (Table 2 ) Nobori et al., 1994) . These include melanoma, acute lymphocytic leukemia, osteosarcoma, lung, brain, breast, head and neck, bladder, and ovarian cancers. The frequent inactivation of INK4A in these tumors suggests that the loss of INK4A provides a selective cellular growth advantage. INK4B is encoded immediately adjacent to INK4A at the INK4 locus, 9p21. Its expression is induced in response to transforming-growth factor beta (TGF-β) treatment (Hannon and Beach, 1994) . The INK4B sequence is very similar to INK4A, about 70% at the amino acid level. Its nearly identical biochemical behavior, as an inhibitor of CDK4/6, supports the notion that INK4B might be a player in tumor suppression. Although evidence for the tumor suppressor role of INK4B is abundant, the INK4B role in tumor suppression is unclear. No, or rare, point mutations have identified INK4B in tumor cell lines. The majority of homozygous deletions affect either both the INK4A and INK4B loci, or INK4A alone in most tumors (Rocco and Sindransky, 2001) . Specific deletions of INK4B have been found in only a few cases of leukemia and lymphomas (Nguyen et al., 2000; Vidal and Koff, 2000; Rocco and Sindransky, 2001) . In contrast, the hypermethylation of INK4B seems to be frequent in several cancers (Cameron et al., 1999; Nguyen et al., 2000; Wong et al., 2000; Chim et al., 2001) . This suggests that the silencing of the INK4B promoter by methylation plays an important role in tumor development.
The second family of CKIs is the CIP/KIP family, which shares homology at the N-terminal CDK inhibitory domain. This includes p21(CIP1/WAF1), p27 (KIP1), and p57 (KIP2). The p21 CIP1 binds and inhibits several CDK-cyclin complexes, including CDK2-cyclin E and CDK4-cyclin D1. The p21 CIP1 expression is directly induced by p53 (Sherr, 1994) . This immediately focuses attention on p21 CIP1 as a potential mediator of p53-dependent tumor suppression. Furthermore, the overexpression of p21 CIP1 can cause G1 arrest. So far, however, there have been no reports of p21 CIP1 alterations in tumors or cell lines. If p21
CIP1 is an important mediator in the p53-dependent tumor suppression, then the mutations of p21 CIP1 might be expected in some fraction of tumors and cell lines. Therefore, the genetic evidence of p21 CIP1 as a general tumor suppressor is still undetermined.
The p27 KIP1 was identified as CDK-binding proteins that are activated by TGF-β, contact inhibition of cell growth (Polyak et al., 1994; Toyoshima and Hunter, 1994) . The p27 KIP1 protein sequence bears some similarities to p21, and also inhibits several CDKs. No mutations in the p27 KIP1 gene have been reported in tumor and cell lines. However, the reduced expression of p27 KIP1 is frequently detected in human cancers. These include the breast, prostate, gastric, lung, skin, colon, and ovarian cancers (Catzavelos et al., 1997; Esposito et al., 1997; Mori et al., 1997; Loda et al., 1997; Porter et al., 1997; CordonCardo et al., 1998; Florenes et al., 1998) . Surprisingly, however, a relatively high expression of p27 KIP1 is found in a series of human esophageal cancer cell lines . Furthermore, several human colon and breast cancer cell lines also express high levels of p27 KIP1 , but low levels in three normal human mammary cell lines. It is also overexpressed in the small-cell carcinomas of the lung, despite their high degree of malignancy (Yatabe et al., 1997) . The increased expression of p27 KIP1 in cancer cells seems paradoxical, because mutations of this gene have not been found or are extremely rare in various cancers (Sgambato et al., 2000) . A possible expression for the increase of p27 KIP1 in some cancer cells is that they have become refractory to the inhibitory effects of this protein. Further studies will be required to establish the role of p21 CIP1 and p27 KIP1 in cancer development.
Cell Cycle Control and Cancer Treatment
The frequent loss of cell cycle regulation in human cancer has revealed targets for possible therapeutic intervention. Indeed, (Chen et al., 1999) . CDKs are actively being targeted, due to their central role in the control of cell cycle progression. Designing inhibitors that block CDK activity are the most direct and promising strategy. Substantial efforts from many groups have led to the discovery, optimization, and characterization of potent CDK inhibitors. Three properties make CDK inhibitors attractive as anti-tumor agents. First, they are potent anti-proliferative agents, arresting cells in G1 or G2/M (Damiens et al., 2000; Soni et al., 2001) . Second, they trigger apoptosis, alone or in combination with other treatments (Edamatsu et al., 2000) . Third, in some instances, the inhibition of CDKs contributes to the cell differentiation (Matushansky et al., 2000) . Only reports on the clinical trials of flavopiridol and UCN01 (7-hydroxystaurosporine) are available, but several other CDK inhibitors are currently being researched. Potential gene therapeutic strategies are also being established, based on the negative regulators of cell cycle progression (such as INK4A, p21
CIP1
, and p27 KIP1 ) to inhibit cell transformation and cancer growth. The use of gene therapy continues to be a promising, yet elusive, alternative for the treatment of cancer. The origins of cancer must be well understood so that the therapeutic gene can be chosen that has the highest chance of successful tumor regression. The gene delivery system must be tailored for optimum transfer of the therapeutic gene to the target tissue. In the near future, new drug compounds and gene therapy protocols will be available. They will help the fight against cancer, since they will broaden our understanding of the cell cycle and cancer.
